Tirzepatide reduced left ventricular mass by 11 grams and paracardiac fat by 45 mL compared to placebo in patients with obesity-related heart failure with preserved ejection fraction.
−11 g LV mass (P=0.004)Placebo-corrected reduction in left ventricular mass after 52 weeks of tirzepatide in obesity-related HFpEF
What the researchers found
In 106 patients with obesity-related heart failure with preserved ejection fraction (HFpEF), tirzepatide reduced left ventricular (LV) mass by 11 g (95% CI: -19 to -4 g, P = 0.004) and paracardiac adipose tissue by 45 mL (95% CI: -69 to -22 mL, P < 0.001) compared to placebo over 52 weeks.
The reduction in LV mass correlated with weight loss (P < 0.02) and tended to correlate with waist circumference and blood pressure changes (P = 0.06 for both). LV mass changes also correlated with reductions in LV end-diastolic volume and left atrial volumes (P < 0.03 for all), indicating broader cardiac remodeling benefits.
Why it matters
Obesity-related heart failure is a growing health crisis, and excess fat around the heart worsens cardiac function. This study provides imaging evidence that tirzepatide doesn't just help with weight loss — it directly reduces harmful structural changes in the heart. These findings help explain why tirzepatide reduced heart failure events in the main SUMMIT trial.
How the study worked
This was a substudy of the SUMMIT randomized controlled trial. 175 patients with obesity-related HFpEF underwent cardiac MRI at baseline, with 106 completing scans at both baseline and 52 weeks. Patients received tirzepatide (starting at 2.5 mg weekly, increasing to a maximum of 15 mg weekly via subcutaneous injection) or placebo. Researchers measured heart muscle mass, chamber volumes, and fat around the heart using multi-angle MRI sequences.
What this study cannot tell us
The substudy included only 106 of the 731 patients from the parent trial, limiting statistical power. The study was not powered to detect changes in clinical outcomes like hospitalizations or death. Image quality issues excluded some participants. The 52-week follow-up may not capture long-term effects, and the correlation between weight loss and cardiac changes makes it difficult to determine whether tirzepatide has direct cardiac effects independent of weight loss.
How to read the evidence
This is a prespecified substudy of a phase 3 randomized, double-blind, placebo-controlled trial (SUMMIT), published in a top-tier cardiology journal. While the imaging substudy had a modest sample size, the design and statistical rigor are strong.
When this study was published
Published in 2025, this is a very recent study reflecting the latest evidence on tirzepatide's cardiac effects from the landmark SUMMIT trial.
The bigger picture
GLP-1/GIP receptor agonists like tirzepatide are reshaping treatment for obesity and its complications. This cardiac imaging substudy adds to a growing body of evidence that these peptide therapies provide benefits beyond weight loss, including direct improvements to heart structure. As obesity-related heart failure becomes more prevalent, understanding how these drugs remodel the heart could guide treatment strategies.
Questions still open
- Does tirzepatide's reduction in heart fat and muscle mass translate into fewer heart failure hospitalizations and improved survival long-term?
- Are the cardiac structural improvements maintained after the drug is discontinued, or do they reverse with weight regain?
- Does tirzepatide have direct cardiac effects beyond those explained by weight loss alone?
Common questions
What is tirzepatide and how does it work?
What is paracardiac adipose tissue and why does it matter?
Read the original research
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.
Journal of the American College of Cardiology, 85(7), 699-706
Citation
Kramer, Christopher M; Borlaug, Barry A; Zile, Michael R; Ruff, Dustin; DiMaria, Joseph M; Menon, Venu; Ou, Yang; Zarante, Angela M; Hurt, Karla C; Murakami, Masahiro; Packer, Milton. (2025). Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy.. Journal of the American College of Cardiology, 85(7), 699-706. https://doi.org/10.1016/j.jacc.2024.11.001